|
|
Sanofi CEO
Oct 27, 2014 21:29:41 GMT -5
via mobile
Post by pmikeks on Oct 27, 2014 21:29:41 GMT -5
I'm sure everybody is aware of the strategy struggle within Sanofi top management. The CEO is asking the Board of Directors not to fire him. This is probably old news to a lot of you but I wonder how this 'strategy struggle ' may effect the rollout and market plan of Mannkind.
|
|
|
|
Post by liane on Oct 28, 2014 4:41:43 GMT -5
|
|
|
|
Post by suebeeee1 on Oct 28, 2014 8:28:54 GMT -5
They mentioned Afrezza. That was the one item I was looking for. We are part of the public plan! Yay!
|
|
|
|
Post by otherottawaguy on Oct 28, 2014 8:41:51 GMT -5
I see Sanofi is taking close to a 10% haircut here at the open.
|
|
|
|
Post by otherottawaguy on Oct 28, 2014 8:45:02 GMT -5
Sanofi Q3 presentation Afrezza mention
Global Licensing Agreement with Mannkind for Afrezza® in Q3 2014 Expands Diabetes Portfolio
-Afrezza® has the potential to address resistance to insulin initiation and insulin intensification, a major problem in the suboptimal treatment of diabetes
-PK profile of Afrezza®, a rapid-acting inhaled insulin, can simulate the natural prandial insulin response
-Inhaler is an innovative, unique and patient friendly device that helps patients overcome many of the barriers to insulin treatment
-Launch of Afrezza® in the U.S. is expected in Q1 2015
Afrezza got a mention in the Q&A as well.
OOG
|
|
|
|
Post by spiro on Oct 28, 2014 8:48:21 GMT -5
From YMB ? Very interesting,
lakers_w • 29 minutes ago
4users liked this postsusers disliked this posts0Reply
3Q14 SNY ER Appendix 6, pg 23 indicates SNY working on inhaled GLP-1 Phase I, $$$ for Technosphere
en.sanofiDOTcom/Images/37449_20141027_Q32014Results_en.pdf
Afrezza was mentioned on pg 3,10.
Appendix 6, pg23 shows R&D Pipeline.
Phase I:
SAR425899
GLP-1 / GCGR agonist Diabetes
SAR342434
Insulin Lispro Diabetes
Pg 22, Phase III:
Lyxumia® (lixisenatide)
GLP-1 agonist Type 2 diabetes, U.S
LixiLan
lixisenatide + insulin glargine Fixed-Ratio / Type 2 diabetes Less
|
|
|
|
Post by ashiwi on Oct 28, 2014 9:03:56 GMT -5
November 20th is the day we need to look forward to.
From the SNY press release today>>>
"...we are hosting an IR thematic seminar on New
Medicines on November 20th in Boston, where we look forward to discussion of
some of our upcoming launches in greater detail."
I doubt MNKD's conference call on Monday will reveal much new info. It's all in Sanofi's hands now.
|
|
|
|
Post by spiro on Oct 28, 2014 9:57:19 GMT -5
I am not sure the YMB poster is correct. I have been unable to find anything to confirm that Technosphere is being used.
|
|
|
|
Post by kc on Oct 28, 2014 12:09:09 GMT -5
|
|
